Compare Microchip Technology Inc. (MCHP) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Microchip Technology Inc. vs Smith & Nephew plc — how do they compare? Microchip Technology Inc. trades at $75.55 (market cap $41.01B), while Smith & Nephew plc trades at $27.24 (market cap $11.10B). The key difference: Microchip Technology Inc. is far larger — about 3.7× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.95%). Which is the better fit depends on your goals — on Pluang, investors hold Microchip Technology Inc. for 63 Days and Smith & Nephew plc for 121 Days on average.
| MCHP | SNN | |
|---|---|---|
Market Cap | $41.01B | $11.10B |
Volume | 9,972,516 | 1,051,703 |
Sector | Technology | Health |
52-Week High | $102.97 | $37.17 |
52-Week Low | $49.02 | $26.42 |
Typical Hold Time | 63 Days | 121 Days |
Enterprise Value | $46.13B | $14.13B |
Dividend Yield | 2.41% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MCHP trades at $75.52, down 3.2% over 24 hours, with a bearish technical signal from moving averages. The company reported a net loss of -$500K in 2025, though it has beaten EPS estimates in recent quarters. Analyst consensus is strongly bullish with a $110.50 price target, supported by positive news on product expansions in Ethernet and 48V power portfolios and the completion of the Hailo acquisition.
The outlook is mixed: strong analyst support and strategic expansions in high-growth areas like AI and automotive present upside, but high valuation ratios, significant debt, and recent profitability challenges pose risks. Investor sentiment is cautiously optimistic amid sector tailwinds.
Smith+Nephew (SNN) trades at $27.24, near its 52-week low of $27.05, with a bearish technical signal despite recent earnings beats. Revenue grew to $6.16B in 2025, with net income margin improving to 10.08%, but the stock faces headwinds from analyst downgrades and CFO departure news. Product launches like the EVOS PELVIC System highlight innovation, yet investor sentiment remains cautious.
The outlook is mixed: strong fundamentals and undervaluation (P/E 18.34) offer upside, but technical weakness and competitive risks temper near-term gains. Key risks include execution challenges and market volatility, while institutional interest (e.g., BlackRock's $505M stake) provides support. Investors should weigh solid profitability against sentiment-driven price pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Microchip Technology Inc.
Microchip became an independent company in 1989 when it was spun off from General Instrument. More than half of revenue comes from MCUs, which are used in a wide array of electronic devices from remote controls to garage door openers to power windows in autos. The company's strength lies in lower-end 8-bit MCUs that are suitable for a wider range of less technologically advanced devices, but the firm has expanded its presence in higher-end MCUs and analog chips as well.
Read more on MCHP →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
